PDF Cover

Endoscopic Retrograde Cholangiopancreat Market

The market for Endoscopic Retrograde Cholangiopancreat was estimated at $2.4 billion in 2024; it is anticipated to increase to $4.0 billion by 2030, with projections indicating growth to around $6.0 billion by 2035.

Report ID:DS1801035
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Endoscopic Retrograde Cholangiopancreat
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Endoscopic Retrograde Cholangiopancreat Market Outlook

Revenue, 2024

$2.4B

Forecast, 2034

$5.5B

CAGR, 2025 - 2034

8.7%

The Endoscopic Retrograde Cholangiopancreat industry revenue is expected to be around $2.6 billion in 2025 and expected to showcase growth with 8.7% CAGR between 2025 and 2034. The increasing prominence of ERCP is a reflection of its growing clinical and financial significance to the field of gastrointestinal endoscopy. Since they can treat patients with complex biliary and pancreatic disease with minimally invasive treatments thus lowering the expenses associated with their care, hospitals are increasingly relying on this technology. The increasing incidence of pancreatic cancer and the growing number of gallstone related complications are driving the markets expansion. Additionally, preference for minimally invasive procedures, such as endoscopy, over traditional surgery is another factor, as is the improving technology in the ERCP devices and endoscopic imaging. Reusable systems accounted for the majority of the revenue generated by the endoscopic retrograde cholangiopancreatography industry in 2024, at $1.54 billion. Dominance of reusable systems in ERCP sales is due to their presence in high volume centres. ERCP products for use by others and associated end user categories generated $324 million in sales in 2024, accounting for 16.8% of the market. The ERCP products for use by other and associated end user categories include those used in tertiary hospitals, specialist clinics and in hospital endoscopy units which are increasingly integrating ERCP into their gastrointestinal care services.

Using a procedure called endoscopic retrograde cholangiopancreatography, doctors are able to locate bile and pancreatic ducts. Using a flexible tube with a camera in it, they can see inside the tubes, giving them a clearer picture. They can also inject a special dye into the tubes. ERCP enables doctors to do some treatments like widening narrowed region's, removing gallstones and inserting stents. Endoscopic retrograde procedures are valuable for the evaluation and treatment of patients with conditions affecting the biliary and pancreatic ductal systems. This includes the evaluation and treatment of patients with obstructive jaundice, with or without cholangitis, as well as the evaluation and treatment of patients with bile duct stones. A strong market for endoscopic retrograde cholangiopancreatography services exists due to factors including better single use duodenoscopes, the implementation of digital imaging in procedures to visualise bile ducts, the use of ERCP in out patients and the ERCP training of medical staff.

Endoscopic Retrograde Cholangiopancreat market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Endoscopic Retrograde Cholangiopancreat Market Outlook

Market Key Insights

  • The growth of the ERCP industry is predicted to be from 2.4 billion dollars in 2024 to 5.5 billion dollars in the year 2034. The market has grown at a compound annual growth rate of 8.7%. This growth is attributed to the increasing demand for the treatment of pancreatic diseases, the early detection of pancreatic cancer and the exploration of the biliary system.

  • Leading players in the industry include Boston Scientific Corporation, CONMED Corporation, and Olympus Corporation, these firms being instrumental in the formation of the competitive landscape.

  • The US and German markets are the most significant in the endoscopic retrograde cholangiopancreatogram industry. It is predicted that the annual growth for these countries will be between 6.4% and 9.1% from 2024 to 2030.

  • The highest growth rates, with compound annual growth rates between 8.4 and 10.9%, are predicted for the emerging markets of South Africa, India and Brazil.

  • Technological advancements in ERCP are predicted to enhance the growth of the endoscopic retrograde cholangiopancreatography industry by $185 million by the year 2030.

  • Over the period from 2024 to 2034, the Endoscopic Retrograde Cholangiopancreatography market is due to grow by $3.1 billion. As far as applications are concerned, pancreatic disorders are a prime target for manufacturers.

  • The market for endoscopic retrograde cholangio pancreatography is predicted to rise by 130% by 2034 as compared to 2024. This expansion is owed to the significant increase in digestive disorders and to endoscopy technologys advancements.

endoscopic retrograde cholangiopancreat market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Endoscopic Retrograde Cholangiopancreat - Country Share Analysis

Opportunities in the Endoscopic Retrograde Cholangiopancreat

The growing concern with duodenoscope reprocessing in North America and hospital acquired infections are both prompting a greater need for the use of endoscopes capable of single procedure and advanced auxiliary applications. If community based endoscopy providers are able to join forces with health care systems that offer comprehensive medical services then there are new financial opportunities which may arise. The duodenoscope market valued at 1.54 billion dollars this year is also expected to increase to 2.34 billion by the year 2030. Growth in this market will come from the use of single use duodenoscopes and from the application of AI in endoscopy.

Growth Opportunities in North America and Asia-Pacific

Advanced gastroenterology suites in North America, coupled with robust insurance policies, boost the demand for ERCP treatment. ASCs are taking over ERCP procedures and will become the largest customers for ERCP procedures, as these procedures are transferred to cheaper out patient centres. The high endoscopes used for treating gallstones and pancreatic duct imaging are highly competitive with suppliers offering different levels of infection control, lower reprocessing costs and accessories. ASCs are the perfect fit for ERCP contracts, ERCP treatment kits, and ERCP software which can speed up the ERCP treatment. Furthermore, ERCP support is also subscription based and ERCP treatments can now be performed at a higher complexity.
The Asia Pacific endoscopic retrograde cholangiopancreatogram sector is driven by a growing hospital infrastructure, an increase in the number of biliary disease sufferers and endoscopists opting for ERCP over surgery, Hospitals are the primary source of ERCP. Major ERCP manufacturers are both multinational and local, price competition for ERCP consumables and equipment has grown, opening opportunities for higher priced ERCP systems suited to large city hospitals. ERCP sales may also be boosted by partnerships with training facilities, the development of new techniques and co operation with Hospitals to boost patient numbers and introduce new procedures such as cholangioscopy and sphincterotomy in towns where ERCP is used frequently.

Market Dynamics and Supply Chain

01

Driver: Rise in Digestive Disorders

The rise in disorders globally has also led to a surge in the demand for endoscopic retrograde cholangiopancreatography (ERCP) procedures—particularly due to chronic conditions like gallstones and pancreatitis as well as biliary tract cancers driving the growth of the ERCP sector forward significantly. The invasive diagnostic and treatment capabilities of ERCP have also made it a favored option, among healthcare professionals.
Recent progress in the realm of endoscopy has also significantly enhanced the ERCP industrys growth trajectory. These advancements have also paved the way for cutting edge definition and 3D imaging technologies that offer enhanced and intricate visual representations. Moreover they have also bolstered the safety, efficiency and efficacy of ERCP procedures in terms of both diagnosis and treatment. Breakthrough innovations such, as guidewire assisted cannulation, single operator cholangioscopy and endoscopic ultrasonography exemplify this transformative evolution.
02

Restraint: High Cost of ERCP Procedures

The price of Endoscopic Retrograde Cholangiopancreatography (ERCP) varies significantly depending on the location and type of healthcare facility where it is performed. The high expenses associated with the procedure stem not only from the ERCP itself but also from hospitalization, endoscopic equipment, and follow-up medical care. This creates a challenge, as many individuals in low- and middle-income countries may find these costs prohibitive, resulting in a smaller pool of potential patients.
03

Opportunity: Shift toward outpatient minimally invasive Endoscopic Retrograde Cholangiopancreat expanding procedures in European ambulatory surgical centers and Rising biliary stone disease driving Endoscopic Retrograde Cholangiopancreat adoption in Asia-Pacific tertiary hospitals

With healthcare policy changes in Europe, hospitals are facing mounting pressure to keep inpatient stays as short as possible. As a result, they are referring an increasing number of Endoscopic Retrograde Cholangiopancreatography procedures to high volume outpatient surgical facilities. The design of this technique suits small instruments like slim endoscopes and the latest endotherapy equipment which allow rapid procedures and patients are often able to go home on the same day. By 2030 the global demand for the endoscope devices used for aiding other scopes is predicted to grow at a rate of 11.4% annually from 2024 levels of 0.76 billion to 1.45 billion. It is the endoscope accessories which are expected to rise in use the most, particularly in Western Europe.
The Endoscopic Retrograde Cholangiopancreatography sector in Asia Pacific is being driven by the growing prevalence of pancreaticobiliary disorders and also by the increasing coverage under health insurance in this region. There is a considerable potential for referrals in smaller towns because of the scarcity of specialists in these region's, particularly in instances requiring biliary stenting and complex stone removal. The market for endotherapy devices will expand at the highest rate in this country, and is projected to overtake the global rise from 0.10 billion devices in 2024 to 0.17 billion by 2030. This growth is partly due to hospitals equipping themselves with more modern ERCP devices and adopting minimally invasive ERCP treatments.
04

Challenge: Lack of Skilled Professionals

Performers of ERCP procedures consist of gastroenterologists and surgical gastroenterologists who require specific training for their execution, which contributes to the challenge in carrying out procedures and consequently hampers market expansion due, to the global shortage of these highly skilled professionals.

Supply Chain Landscape

1

Endoscopic Retrograde Cholangiopancreat

Olympus CorporationBoston Scientific Corporation
2

ERCP Devices

Medtronic PLCCONMED Corporation
3

Global Distribution

Telemed System Inc.Olympus Corporation
4

Clinical Applications

HospitalsAmbulatory Surgical CentersGastroenterology Clinics
Endoscopic Retrograde Cholangiopancreat - Supply Chain

Use Cases of Endoscopic Retrograde Cholangiopancreat in Biliary Tract Exploration & Early Detection of Biliary

Biliary Tract Exploration : Endoscopic Retrograde Cholangiopancreatography (ERCP) is commonly utilized to diagnose and address issues within the tract like gallstones or inflammation effectively in a single procedure without the requirement for invasive surgeries. Companies like Olympus Corporation are, at the forefront of offering ERCP endoscopes and associated equipment.
Pancreatic Disease Management : ERCP plays a role in treating different pancreatic issues such as chronic pancreatitis and obstructions in the pancreatic duct by facilitating drainage and inserting stents directly through visualization and management of abnormalities in the pancreas without invasive procedures thus shortening the recovery period significantly Companies, like Medtronic are known for offering extensive ERCP solutions.
Early Detection of Biliary and Pancreatic Cancer : ERCPs importance lies in its capacity to detect pancreatic cancers at an early stage when diagnosis is challenging. Expert evaluation through tissue sampling and imaging enhances the likelihood of an outcome. Boston Scientific Corporation plays a role in advancing cancer detection through ERCP innovation, in this field.

Recent Developments

The latest trends in the Endoscopic Retrograde Cholangiopancreatography (ERCP) market show a changing landscape influenced mainly by advancements in technology and innovation, by medical technology firms introducing cutting edge ERCP equipment.

March 2024 : Medtronic has unveiled a robotic endoscopic system designed to enhance the accuracy of ERCP procedures and improve treatment effectiveness.
May 2024 : A new advanced duodenoscope has been introduced by Olympus Corporation to improve the clarity, for ERCP procedures. This enhancement aims to enhance accuracy and treatment effectiveness.
August 2024 : Boston Scientific launched the Beacon Pancreatic Stent System to enhance safety and procedural efficiency during ERCP procedures. This addition expands their product range.

Impact of Industry Transitions on the Endoscopic Retrograde Cholangiopancreat Market

As a core segment of the Medical Device industry, the Endoscopic Retrograde Cholangiopancreat market develops in line with broader industry shifts. Over recent years, transitions such as Technological Advancements in ERCP and Shift towards Disposable ERCP Devices have redefined priorities across the Medical Device sector, influencing how the Endoscopic Retrograde Cholangiopancreat market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Technological Advancements in ERCP

Technological progress in ERCP is driving the global market for endoscopic retrograde cholangiopancreatography in a direction away from conventional endoscopic equipment and towards digital and high definition ERCP systems which bring about a higher clinical value and revenue streams. Advanced imaging technologies such as the Spyglass direct visualisation system and narrow band imaging greatly enhance diagnostic precision, improve the success rate of procedures and make therapeutic ERCPs more efficient. This has resulted in a greater use of these technologies in complex biliary and pancreatic diseases. By 2030 advancements in endoscopic retrograde cholangiopancreatography technology with superior real time decision support features and high quality visualisation will contribute $185 million to the market. The benefits of this continuous improvement are that digital imaging technology and associated computer systems are enabling better patient outcomes and faster technological advancements which in turn allow hospitals to charge more for procedures and replace outdated equipment.
02

Shift towards Disposable ERCP Devices

The trend in ERCP is towards the use of single use/disposable ERCP products in hospitals.